discontinuing glp 1 Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years ISPOR 2025: Exploring reasons for

(1.25 CE Credits)

Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years

Companies operating in this space may benefit from reviewing their promotional materials to ensure alignment with FDA expectations

Using GLP-1RAs instead of insulin cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and saved US$19,391 and US$10,293, respectively, from the healthcare sector perspective

Designed for athletes, used by all